Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber

Alexandra Thrope1, Sameera Ramjan2, Charlie White3

  • 1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Pediatric Blood & Cancer
|January 10, 2026
PubMed

Insights

Children treated for acute lymphoblastic leukemia (ALL) may experience neurocognitive changes. Older age and female sex are linked to poorer outcomes in attention and memory, suggesting a need for early intervention.

Area of Science:

  • Pediatric Oncology
  • Neuroscience
  • Clinical Psychology

Background:

  • Children undergoing treatment for acute lymphoblastic leukemia (ALL) face risks of neurocognitive deficits.
  • These deficits can affect attention, working memory, executive functions, and psychomotor speed.

Purpose of the Study:

  • To evaluate longitudinal neurocognitive trajectories in children with newly diagnosed ALL.
  • To identify medical and demographic factors associated with these neurocognitive outcomes during treatment.

Main Methods:

  • 298 patients aged 3-21 with ALL were assessed using Cogstate at four timepoints.
  • Linear mixed models analyzed trajectories and interactions with clinical factors, accounting for patient and site variability.

Main Results:

  • Significant longitudinal changes were observed in executive functioning, attention, visual learning, and working memory accuracy (p < 0.001).
  • Older age correlated with worse psychomotor function and working memory speed, while female sex was associated with poorer psychomotor and working memory accuracy but better visual learning and working memory speed.
  • A notable proportion of participants performed below -1.5 SD in attention, executive functioning, and psychomotor functioning.

Conclusions:

  • Most patients showed normal neurocognitive functioning with variable trajectories.
  • A subgroup exhibited poor performance in attention, executive functioning, and psychomotor skills.
  • Older age at diagnosis and female sex are identified as risk factors, highlighting potential targets for early intervention.
Abstract

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...